THE EFFICACY OF POSACONAZOLE FOR PROPHYLAXIS OF INVASIVE MYCOSES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
Efficacy of posaconazole for prophylaxis was evaluated in 77 chemotherapy cycles in 59 patients with acute myeloid leukemia (AML) aged 39 (17–62) years from 2012 till 2017. Posaconazole was given in oral suspension 200 mg three times a day after meal during chemotherapy cycle or on 1st day after t...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2017-11-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/2176 |
| _version_ | 1797841402604814336 |
|---|---|
| author | G. A. Klyasova V. A. Okhmat E. N. Parovichnikova E. O. Gribanova V. V. Troitskaya V. G. Savchenko |
| author_facet | G. A. Klyasova V. A. Okhmat E. N. Parovichnikova E. O. Gribanova V. V. Troitskaya V. G. Savchenko |
| author_sort | G. A. Klyasova |
| collection | DOAJ |
| description | Efficacy of posaconazole for prophylaxis was evaluated in 77 chemotherapy cycles in 59 patients with acute myeloid leukemia (AML) aged 39 (17–62) years from 2012 till 2017. Posaconazole was given in oral suspension 200 mg three times a day after meal during chemotherapy cycle or on 1st day after the cycle. Administration of posaconazole predominated in patients with de novo AML (84.5%) on 1st induction cycles (66.3%). Neutropenia was present in all patients with median duration of 22 days. Median duration of prophylaxis was 21 (2–57) days. Posaconazole prophylaxis was interrupted in 28 (36.4%) of 77 cases, mainly due to diarrhea (28.6%). In 17 (61%) of 28 cases prophylaxis was resumed within a median of 3 days. In 72 (93.5%) of cases duration of posaconazole prophylaxis was ≥ 7 days, in 5 (6.5%) cases < 7 days. Efficacy of prophylaxis was evaluated in cases of posaconazole duration ≥ 7 days. Invasive pulmonary aspergillosis (probable) was in 2 (2.7%) of 72 cases. Administration of posaconazole with duration ≥ 7 days was in 46 cases on chemotherapy cycle, in 26 cases – on first day after the cycle. Patients using Posaconazole after a course of chemotherapy in comparison with patients receiving the drug in the first days of the course had significantly less interruptions of prophylaxis (11,5% vs 41,3%, p=0.009) and a reduction in duration of Posaconazole using (19 days vs 27 days, p=0.007).One case of invasive aspergillosis was registered in each group.We confirmed the efficacy of posaconazole for prophylaxis of invasive mycoses in patients with AML. Administration of posaconazole prophylaxis on first day after the end of chemotherapy cycle results in saving of drug by reducing duration of posaconazole using by 8 days and does not increase the incidence of invasive mycoses. |
| first_indexed | 2024-04-09T16:30:17Z |
| format | Article |
| id | doaj.art-f915fdc90da64f0aba234d3165a1d17f |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:30:17Z |
| publishDate | 2017-11-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-f915fdc90da64f0aba234d3165a1d17f2023-04-23T06:57:07ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902017-11-0101411812410.21518/2079-701X-2017-14-118-1242152THE EFFICACY OF POSACONAZOLE FOR PROPHYLAXIS OF INVASIVE MYCOSES IN PATIENTS WITH ACUTE MYELOID LEUKEMIAG. A. Klyasova0V. A. Okhmat1E. N. Parovichnikova2E. O. Gribanova3V. V. Troitskaya4V. G. Savchenko5National Research Center for HematologyNational Research Center for HematologyNational Research Center for HematologyNational Research Center for HematologyNational Research Center for HematologyNational Research Center for HematologyEfficacy of posaconazole for prophylaxis was evaluated in 77 chemotherapy cycles in 59 patients with acute myeloid leukemia (AML) aged 39 (17–62) years from 2012 till 2017. Posaconazole was given in oral suspension 200 mg three times a day after meal during chemotherapy cycle or on 1st day after the cycle. Administration of posaconazole predominated in patients with de novo AML (84.5%) on 1st induction cycles (66.3%). Neutropenia was present in all patients with median duration of 22 days. Median duration of prophylaxis was 21 (2–57) days. Posaconazole prophylaxis was interrupted in 28 (36.4%) of 77 cases, mainly due to diarrhea (28.6%). In 17 (61%) of 28 cases prophylaxis was resumed within a median of 3 days. In 72 (93.5%) of cases duration of posaconazole prophylaxis was ≥ 7 days, in 5 (6.5%) cases < 7 days. Efficacy of prophylaxis was evaluated in cases of posaconazole duration ≥ 7 days. Invasive pulmonary aspergillosis (probable) was in 2 (2.7%) of 72 cases. Administration of posaconazole with duration ≥ 7 days was in 46 cases on chemotherapy cycle, in 26 cases – on first day after the cycle. Patients using Posaconazole after a course of chemotherapy in comparison with patients receiving the drug in the first days of the course had significantly less interruptions of prophylaxis (11,5% vs 41,3%, p=0.009) and a reduction in duration of Posaconazole using (19 days vs 27 days, p=0.007).One case of invasive aspergillosis was registered in each group.We confirmed the efficacy of posaconazole for prophylaxis of invasive mycoses in patients with AML. Administration of posaconazole prophylaxis on first day after the end of chemotherapy cycle results in saving of drug by reducing duration of posaconazole using by 8 days and does not increase the incidence of invasive mycoses.https://www.med-sovet.pro/jour/article/view/2176posaconazoleantifungal prophylaxisinvasive mycoseshematological malignanciesacute leukemiaaml |
| spellingShingle | G. A. Klyasova V. A. Okhmat E. N. Parovichnikova E. O. Gribanova V. V. Troitskaya V. G. Savchenko THE EFFICACY OF POSACONAZOLE FOR PROPHYLAXIS OF INVASIVE MYCOSES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA Медицинский совет posaconazole antifungal prophylaxis invasive mycoses hematological malignancies acute leukemia aml |
| title | THE EFFICACY OF POSACONAZOLE FOR PROPHYLAXIS OF INVASIVE MYCOSES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA |
| title_full | THE EFFICACY OF POSACONAZOLE FOR PROPHYLAXIS OF INVASIVE MYCOSES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA |
| title_fullStr | THE EFFICACY OF POSACONAZOLE FOR PROPHYLAXIS OF INVASIVE MYCOSES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA |
| title_full_unstemmed | THE EFFICACY OF POSACONAZOLE FOR PROPHYLAXIS OF INVASIVE MYCOSES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA |
| title_short | THE EFFICACY OF POSACONAZOLE FOR PROPHYLAXIS OF INVASIVE MYCOSES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA |
| title_sort | efficacy of posaconazole for prophylaxis of invasive mycoses in patients with acute myeloid leukemia |
| topic | posaconazole antifungal prophylaxis invasive mycoses hematological malignancies acute leukemia aml |
| url | https://www.med-sovet.pro/jour/article/view/2176 |
| work_keys_str_mv | AT gaklyasova theefficacyofposaconazoleforprophylaxisofinvasivemycosesinpatientswithacutemyeloidleukemia AT vaokhmat theefficacyofposaconazoleforprophylaxisofinvasivemycosesinpatientswithacutemyeloidleukemia AT enparovichnikova theefficacyofposaconazoleforprophylaxisofinvasivemycosesinpatientswithacutemyeloidleukemia AT eogribanova theefficacyofposaconazoleforprophylaxisofinvasivemycosesinpatientswithacutemyeloidleukemia AT vvtroitskaya theefficacyofposaconazoleforprophylaxisofinvasivemycosesinpatientswithacutemyeloidleukemia AT vgsavchenko theefficacyofposaconazoleforprophylaxisofinvasivemycosesinpatientswithacutemyeloidleukemia AT gaklyasova efficacyofposaconazoleforprophylaxisofinvasivemycosesinpatientswithacutemyeloidleukemia AT vaokhmat efficacyofposaconazoleforprophylaxisofinvasivemycosesinpatientswithacutemyeloidleukemia AT enparovichnikova efficacyofposaconazoleforprophylaxisofinvasivemycosesinpatientswithacutemyeloidleukemia AT eogribanova efficacyofposaconazoleforprophylaxisofinvasivemycosesinpatientswithacutemyeloidleukemia AT vvtroitskaya efficacyofposaconazoleforprophylaxisofinvasivemycosesinpatientswithacutemyeloidleukemia AT vgsavchenko efficacyofposaconazoleforprophylaxisofinvasivemycosesinpatientswithacutemyeloidleukemia |